Grants and Contracts Details
The NCI designated UK Markey Cancer Center (UK MCC), will serve as a consortium institution evaluating therapeutic agents for phase 1 and 2 evaluation under the guidance of the Experimental Therapeutics Clinical Trials Network (ETCTN) of the National Cancer Institute (NCI) in LAO-007, led by The Ohio State University (OSU). The site prioritize the ETCTN goals for early-stage clinical development of novel cancer treatments, including NCI-IND agents consistent with national priorities for developmental therapeutics clinical cancer research. The site will provide efficient and timely activation and conduct of clinical trials that meet regulatory requirements and Good Clinical Practice (GCP) standards and principles, promote collaboration and coordination with OSU both in scientific and patient-care aspects of early phase clinical trials. Dr. Susanne Arnold, PI of this subcontract and MPI and AO Lead of the UM1 grant along with PI, Dr. William Carson at Ohio State University, shares overall scientific and institutional financial responsibility for the ETCTN program, assists with oversight of the clinical trials and patient accruals, has joint decision authority regarding selection of projects to pursue, assigns opportunities to investigators, and will assure proper regulatory and safety requirements for the clinical trials open under the UM1, as well as the ethical conduct of all clinical and laboratory research activities. She assists with development of concepts and submission of proposals for consideration to the Institutional Drug Branch (IDB) of the NCI’s Cancer Therapy Evaluation Program. She will attend monthly LAO-007 phone teleconferences and other teleconferences as needed, in collaboration with other consortium members. She will serve on the NCI’s IDB Steering Committee, review all portfolio trials and oversee work for projects involved in the UM1 at UK MCC site, and attend the ETCTN meeting with other UM1 investigators at a minimum twice annually. Dr. DiPaola will serve as mentor, and advisor to Drs. Arnold as he transitions from his role as MPI to Co-investigator on this grant. He will also oversee efforts to develop new trial proposals based on UK science as well as lead and participate in specific efforts toward GU malignancies.
|Effective start/end date
|5/5/20 → 2/28/22
- Ohio State University: $103,711.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.